GSA Capital Partners’s Summit Therapeutics SMMT Stock Holding History

GSA Capital Partners’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$166K	Buy	+11,423	New	+$203K	0.01%	1572
2025 Q3	–	Sell	-16,963	Closed	-$361K	–	2053
2025 Q2	$361K	Buy	16,963 +1,312	+8%	+$29.9K	0.03%	1147
2025 Q1	$302K	Sell	15,651 -22,831	-59%	-$458K	0.03%	1149
2024 Q4	$687K	Buy	+38,482	New	+$746K	0.05%	671
2023 Q1	–	Sell	-12,500	Closed	-$53K	–	1903
2022 Q4	$53K	Buy	+12,500	New	+$22.7K	0.01%	1356

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

GSA Capital Partners's SMMT Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 11,423 shares worth $166K. The stake represents 0.01% of the portfolio and ranks #1572 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in SMMT as recently as Q2 2025.

GSA Capital Partners first reported a position in SMMT in Q4 2022 and has held it in 5 quarters since. The position peaked at $687K in Q4 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

GSA Capital Partners held 11,423 shares of Summit Therapeutics worth $166K as of Q2 2026.
Summit Therapeutics was a new GSA Capital Partners position in Q2 2026.
Summit Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1572 holding.
GSA Capital Partners first reported a position in Summit Therapeutics in Q4 2022 and has held it in 5 quarters since.
GSA Capital Partners's Summit Therapeutics position peaked at $687K in Q4 2024.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.